To include your compound in the COVID-19 Resource Center, submit it here.

HP802-247: Phase IIb data

DFB's Healthpoint Biotherapeutics subsidiary reported data from a double-blind, U.S. Phase IIb trial in 228 patients ages 18 and older with venous leg ulcers of at least 6 weeks in duration, but not more than

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers